• iCRO: scientific poster presentation on Sep 10, 2022: “Challenges to Assess Bone Metastases in Blinded Independent Central Review (BICR) of Breast Cancer Trials Using RECIST 1.1”
• iBiopsy®: scientific poster presentation on Sep 11, 2022: “Artificial Intelligence Supporting Lung Cancer Screening: Computer Aided Diagnosis of Lung Lesions Driven by Morphological Feature Extraction”
• The team will be available at Booth #447, Exhibition Hall 7.2 during the entire industry exhibition duration

Regulatory News:

Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 ESMO (European Society for Medical Oncology) Congress, to be held in Paris, France, September 9-13 (venue: Paris Expo Porte de Versailles).

The Company will present two scientific posters. Details of the sessions include:

255P - Challenges to Assess Bone Metastases in Blinded Independent Central Review (BICR) of Breast Cancer Trials Using RECIST 1.1

Session: Breast Cancer, Metastatic

Date: Sep 10, 2022

Timeslot to meet the scientific team: 12:00 pm – 1:00 pm CEST

Place: Poster Area, Hall 4

919P - Artificial Intelligence Supporting Lung Cancer Screening: Computer Aided Diagnosis of Lung Lesions Driven by Morphological Feature Extraction

Session: New Diagnostic Tools

Date: Sep 11, 2022

Timeslot to meet the scientific team: 12:00 pm – 1:00 pm CEST

Place: Poster Area, Hall 4

During the industry exhibition, Median team will be available at booth #447, Hall 7.2 to discuss the scientific posters, present the latest developments on iBiopsy® LCS CADe/CADx SaMD as well as the Company’s iCRO services for image management in oncology trials including Imaging Lab, intelligent imaging capabilities for drug development. Daily presentation sessions on Imaging Lab are planned at 3:00 pm CEST at booth.

More about the ESMO congress: https://www.esmo.org/meetings/esmo-congress-2022

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005715/en/